Is there another way to take account of noncompliance in randomized controlled trials?

Hewitt, Catherine E.; Torgerson, David J.; Miles, Jeremy N. V.
August 2006
CMAJ: Canadian Medical Association Journal;8/15/2006, Vol. 175 Issue 4, p347
Academic Journal
The article discusses non-compliance in the design and conduct of randomized controlled trials (RCTs). Noncompliance can cause problems at the analysis stage. The ideas behind choosing complier average causal effect (CACE) to analyze trials involving noncompliance is presented. The only disadvantage of CACE approach is that it can produce wider confidence intervals than the ITT and per-protocol analyzes. The ITT is suggested as primary and the CACE as a secondary approach to analysis.


Related Articles

  • Interpreting clinical trials.  // British Medical Journal;11/11/1978, Vol. 2 Issue 6148, p1318 

    Reports on the influence of confidence limits on the conclusiveness of the interpretations of clinical trials in Great Britain. Importance of the information of the calculation to the clinician; Impact of the item of statistical and clinical logic on the design and interpretation of trials;...

  • Sample size considerations for superiority trials in systemic lupus erythematosus (SLE). Moore, Andrew D; Joseph, Lawrence // Lupus;1999, Vol. 8 Issue 8, p612 

    For reasons of efficiency and ethics, sample size calculations are an important part of the design of all clinical trials. This paper highlights the statistical issues inherent to the estimation of sample size requirements in superiority trials particular to SLE. Calculations based on...

  • Confidence intervals for the number needed to treat. Altman, Douglas G // BMJ: British Medical Journal (International Edition);11/07/98, Vol. 317 Issue 7168, p1309 

    Focuses on the number needed to treat (NNT), a useful way of reporting the results of randomized controlled trials. Calculation of the NNT; Description of the confidence interval for the NNT when the difference between the two treatments is not significant; Construction of sensible confidence...

  • Lessons from Darwin: Evolutionary Biology's Implications for Alzheimer's Disease Research and Patient Care. Becker, Robert E. // Current Alzheimer Research;Jul2005, Vol. 2 Issue 3, p319 

    What are the aims appropriate for a science of clinical pharmacology and clinical trials: to test drugs for efficacy and safety in the clinic, to establish the optimal effectiveness and safety of drugs in patient care or both? Current designs of clinical trials test drugs for efficacy and safety...

  • Efficacy of spinal mobilization in the treatment of patients with lumbar radiculopathy due to disc herniation: A randomized clinical trial. Kumar, Senthil P.; Cherian, Preeth John // International Journal of Neurology & Neurosurgery;Jul2011, Vol. 3 Issue 2-4, p65 

    Introduction: Lumbar radiculopathy (LR) secondary to disc herniation is the most disabling clinical condition amongst people with low back pain. The objective of this study was to evaluate the efficacy of spinal mobilization in the treatment of patients with LR in addition to standard...

  • Missing the point (estimate)? Confidence intervals for the number needed to treat. Barrowman, Nicholas J. // CMAJ: Canadian Medical Association Journal;6/25/2002, Vol. 166 Issue 13, p1676 

    Focuses on the number needed to treat, or the average number of patients a clinician needs to treat with a particular therapy to prevent one bad outcome in a clinical trial. Topic of the National Institutes of Health Stroke Scale; Explanation of confidence intervals for absolute risk reduction...

  • Confidence intervals for the first crossing point of two hazard functions. Ming-Yen Cheng; Peihua Qiu; Xianming Tan; Dongsheng Tu // Lifetime Data Analysis;Dec2009, Vol. 15 Issue 4, p441 

    The phenomenon of crossing hazard rates is common in clinical trials with time to event endpoints. Many methods have been proposed for testing equality of hazard functions against a crossing hazards alternative. However, there has been relatively few approaches available in the literature for...

  • Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial. Leader, Arthur; Devroey, Paul; Witjes, Han; Gordon, Keith // Reproductive Biology & Endocrinology;2013, Vol. 11 Issue 1, p1 

    Background: We sought to determine the impact of treatment flexibility on clinical outcomes in either a corifollitropin alfa or recombinant follicle-stimulating hormone (rFSH) protocol. Methods: Post hoc analysis of a prospective, multicenter, randomized, double-blind, double-dummy...

  • Where Does Evidence from New Trials for Schizophrenia Fit with the Existing Evidence: A Case of the Emperor's New Clothes? Jayaram, Mahesh; Rattehalli, Ranganath D.; Adams, Clive E. // Schizophrenia Research & Treatment;2012, p1 

    Advent of "atypical" antipsychotics has spawned new trials in the recent years and the number of such trial reports has been increasing exponentially. As clinicians we have been led to believe that "atypicals" are better than "typicals" despite the odd dissenting voice in academic and clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics